WAM
CERO

Weiss Asset Management’s CERo Therapeutics CERO Stock Holding History

Weiss Asset Management’s Portfolio CERO Stock Details CERO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-103
Closed -$2.07M – 663
2022
Q3 		$2.07M Hold
103
– – 0.05% 388
2022
Q2 		$2.06M Sell
103
-130
-56% -$2.6M 0.05% 374
2022
Q1 		$4.67M Hold
233
– – 0.1% 260
2021
Q4 		$4.63M Buy
+233
New +$4.63M 0.1% 291

Other funds holding CERO

SCM
Saba Capital Management New York $3.62B AUM 12.96% 1-Year Est. Return
HSBC Holdings
HSBC Holdings London, United Kingdom $192B AUM 27.2% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
WCMNY
Westchester Capital Management (New York) Valhalla, New York $2.21B AUM 26.02% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.02% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.27% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return
HIM
HGC Investment Management Toronto, Ontario, Canada $451M AUM 8.76% 1-Year Est. Return
FTCM
First Trust Capital Management Chicago, Illinois $1.9B AUM 58.28% 1-Year Est. Return
WRBC
W.R. Berkley Corp Greenwich, Connecticut $1.86B AUM 14.44% 1-Year Est. Return

Weiss Asset Management's CERO Position: Q4 2022 in Review

Weiss Asset Management sold out of CERo Therapeutics (CERO) in Q4 2022, closing a stake of 103 shares — an estimated $2.07M sold.

Weiss Asset Management first reported a position in CERO in Q4 2021 and held it in 4 quarters. The position peaked at $4.67M in Q1 2022. 45 funds tracked by Wall St. Rank hold CERO as of Q4 2022.

  • Weiss Asset Management reported no remaining CERo Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Weiss Asset Management sold 103 CERo Therapeutics shares in Q4 2022, an estimated $2.07M.
  • Weiss Asset Management first reported a position in CERo Therapeutics in Q4 2021 and held it in 4 quarters.
  • Weiss Asset Management's CERo Therapeutics position peaked at $4.67M in Q1 2022.
  • 45 funds tracked by Wall St. Rank held CERo Therapeutics as of Q4 2022.

Based on Weiss Asset Management's 13F filing for Q4 2022, filed 14 Feb 2023.